S W Lee1, S H Lee, J-J Yim. 1. Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea.
Abstract
PURPOSE: Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. METHODS: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. RESULTS: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 %) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 %) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 % confidence interval 3.04-226.6). CONCLUSION: Chemoprophylaxis with isoniazid and rifampicin generally decreased IFN-γ levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.
PURPOSE:Interferon-gamma release assay (IGRA) results have been suggested as a surrogate marker of treatment response in latent tuberculosis infection (LTBI). However, data have not been consistent, and most previous studies focused on participants taking isoniazid prophylaxis. The aim of this study was to elucidate the changes in the IGRA results in patients who underwent chemoprophylaxis with isoniazid and rifampicin daily for 3 months. METHODS: In a TB outbreak cohort, 26 asymptomatic close contacts with normal chest radiographs and positive QuantiFERON-TB Gold In-Tube assay (QFT-GIT) results were recruited. These patients were treated with isoniazid and rifampicin daily for 3 months. The QFT-GIT was repeated at 3 and 6 months following treatment initiation. RESULTS: Compared with the initial QFT-GIT results (3.59 ± 3.39 IU/mL), the interferon-gamma (IFN-γ) levels had decreased significantly at 6 months (0.84 ± 1.14 IU/mL; P = 0.005), but not at 3 months (3.58 ± 3.64 IU/mL; P = 0.98). Reversions occurred in seven (26.9 %) patients at 3 months and in an additional two participants at 6 months; a total of nine participants (34.6 %) had reversions. Recent conversion was associated with reversion of the test results (odds ratio 26.3, 95 % confidence interval 3.04-226.6). CONCLUSION: Chemoprophylaxis with isoniazid and rifampicin generally decreased IFN-γ levels among tuberculosis contacts. However, only a small portion of participants achieved reversion.
Authors: J F Broekmans; G B Migliori; H L Rieder; J Lees; P Ruutu; R Loddenkemper; M C Raviglione Journal: Eur Respir J Date: 2002-04 Impact factor: 16.671
Authors: Roland Diel; Robert Loddenkemper; Karen Meywald-Walter; Stefan Niemann; Albert Nienhaus Journal: Am J Respir Crit Care Med Date: 2008-02-14 Impact factor: 21.405
Authors: Seung Heon Lee; Woo Jin Lew; Hee Jin Kim; Hyun-Kyung Lee; Young Min Lee; Chong Hee Cho; Eun Joo Lee; Dong Yeol Lee; Sung Weon Ryu; Soo Yeon Oh; Sin Ok Kim; Tae Sun Shim Journal: Respir Med Date: 2009-10-29 Impact factor: 3.415
Authors: Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Philana Ling Lin; Teresa Coleman; Jonathan P J Carney; Brian J Lopresti; Jaime Tomko; Dan Fillmore; Veronique Dartois; Charles Scanga; L James Frye; Christopher Janssen; Edwin Klein; Clifton E Barry; JoAnne L Flynn Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: A C C Carvalho; R F Schumacher; S Bigoni; E Soncini; L Notarangelo; A Apostoli; C Bonfanti; D Cirillo; P Mantegani; F Porta; M Comelli; A Matteelli Journal: Infection Date: 2013-04-11 Impact factor: 3.553
Authors: John L Johnson; Hendrik Geldenhuys; Bonnie A Thiel; Asma Toefy; Sara Suliman; Bernadette Pienaar; Phalkun Chheng; Thomas Scriba; W Henry Boom; Willem Hanekom; Mark Hatherill Journal: Chest Date: 2014-03-01 Impact factor: 9.410
Authors: Matthew K O'Shea; Thomas E Fletcher; Nicholas J Beeching; Martin Dedicoat; David Spence; Helen McShane; Adam F Cunningham; Duncan Wilson Journal: PLoS One Date: 2014-05-09 Impact factor: 3.240